By a 9-6 vote, a panel of advisers to the Food and Drug Administration has approved Adolor Corp.'s first drug this afternoon. The next step for the Exton drug company is to await a decision by the FDA, which usually follows the advice of its expert panels.
Adolor shares never traded on Wednesday. Trading was halted pending the decision by the Gastrointestinal Drugs Advisory Committee. Adolor shares closed at $4.59 on Tuesday. Look for a small pop in the price on Thursday.
